Evaluating the User Experience of a Smartphone-Delivered Sexual Health Promotion Program for Older Adults in the Netherlands: Single-Arm Pilot Study

BACKGROUND

Sexual health is an important component of quality of life in older adults. However, older adults often face barriers to attaining a fulfilling sexual life because of issues such as stigma, lack of information, or difficult access to adequate support.

OBJECTIVE

We aimed to evaluate the user experience of a self-guided, smartphone-delivered program to promote sexual health among older adults.

METHODS

The mobile app was made available to community-dwelling older adults in the Netherlands, who freely used the app for 8 weeks. User experience and its respective components were assessed using self-developed questionnaires, the System Usability Scale, and semistructured interviews. Quantitative and qualitative data were descriptively and thematically analyzed, respectively.

RESULTS

In total, 15 participants (mean age 71.7, SD 9.5 years) completed the trial. Participants showed a neutral to positive stance regarding the mobile app's usefulness and ease of use. Usability was assessed as "Ok/Fair." The participants felt confident about using the mobile app. To increase user experience, participants offered suggestions to improve content and interaction, including access to specialized sexual health services.

CONCLUSIONS

The sexual health promotion program delivered through a smartphone in a self-guided mode was usable. Participants' perception is that improvements to user experience, namely in content and interaction, as well as connection to external services, will likely improve usefulness and acceptance.

Contribution of cervical cytology in the diagnostic work-up of patients with endometrial cancer

INTRODUCTION

Abnormal cervical cytology in patients with endometrial cancer (EC) has been associated with poor outcome. The aim of this study was to evaluate whether cervical cytology could contribute to an improved preoperative identification of high-grade EC (serous, clear cell, carcinosarcoma, high-grade endometrioid EC) in final histology.

METHODS

A retrospective cohort study was performed in five hospitals in the Netherlands. A total of 554 patients with EC that underwent primary surgical treatment between 2002 and 2010 were included. Primary outcome was defined as the contribution of abnormal cervical cytology in the preoperative identification of high-grade EC. As secondary outcome, recurrence-free survival (RFS) and disease-specific survival were determined based on preoperative cervical cytology, and compared to the currently established risk factors: myometrial invasion, high-grade and lymph vascular space invasion.

RESULTS

Abnormal cervical cytology was present in 45.1%. For patients with preoperative inconclusive and high-grade histology, the presence of abnormal cervical cytology contributed to an improved identification of high-grade EC in final histology (odds ratio [OR] 6.40 [95% confidence interval {CI}: 1.92-21.26]; OR 2.86 [95% CI: 1.14-7.14]), respectively. Patients with abnormal cervical cytology had a significant worse 5-year median RFS. Abnormal cervical cytology was independently related to RFS (hazard ratio 1.67 [95% CI: 1.04-2.68]) and disease-specific survival (hazard ratio 3.15 [95% CI: 1.74-5.71]).

CONCLUSIONS

Abnormal cytology contributes to the preoperative identification of patients with high-grade EC, and is associated with compromised outcome. Future studies are warranted to determine whether cervical cytology could be incorporated into preoperative prediction models for lymph node metastasis.

The value of imaging of the lungs in the diagnostic workup of patients with endometrial cancer

OBJECTIVE

Imaging of the lungs is part of the routine diagnostic workup of patients with endometrial cancer. The present study aimed to determine the incidence of lung metastases in patients with endometrial cancer and to evaluate the clinical relevance of preoperative chest imaging in this population.

METHODS

A retrospective cross-sectional study was performed in four regional and one university hospital in the southeastern part of the Netherlands. A total of 784 patients with epithelial endometrial cancer diagnosed between 2002 and 2010 in five hospitals were included. Patients were followed up for at least 1 year.

RESULTS

Of 784 patients, 541 (69.0%) underwent thoracic imaging and 11 showed findings suspicious for metastases perioperatively or during the 1-year follow-up period. In eight patients, the thoracic metastases were related to their endometrial cancer, resulting in an overall incidence of 1.0% (8/784, 95% CI=0.3-1.7%). These eight patients had high-risk subtypes of endometrial cancer (serous, clear cell or poorly differentiated endometrioid), and the incidence was 4.1% (8/193, 95% CI=1.9-8.3%) for these subtypes. Lung metastases were not detected in any of the patients with low-risk subtypes of endometrial cancer (n=566) at the time of diagnosis (95% CI=0-0.8%).

CONCLUSIONS

The probability of detecting thoracic metastases during the diagnostic workup of patients with endometrial cancer is low. The present data suggest that thoracic imaging could be omitted from the diagnostic workup of patients with low-risk endometrial cancer.

Study on causes and prevention of electrostatic charge build-up during extracorporeal circulation

For many years it has been known that roller pumps interfere regularly with the electrocardiogram (ECG) signal. This electrical activity is also considered responsible for the electrostatic charge build-up in some oxygenators with a plastic heat exchanger. During use of such an oxygenator, an electrical shock can be felt when touching the device. In the absence of a provoked discharge, a spontaneous discharge may occur. The construction of the heat exchanger and the use of nonconductive materials enable some devices to function as a capacitor. If the voltage difference across the fibre wall is too high, an electrostatic discharge may occur. In 1997, four blood-to-water leaks in Maxima Forté oxygenators were reported on a worldwide basis. After thorough research by Medtronic Cardiac Surgery (Cardiopulmonary Division), the cause of the leaks was found to be an electrothermal event across the fibre wall of one single fibre. No patient injuries were reported in any of the events. Medtronic patented a number of US Food and Drug Administration-approved and patient-safe solutions to prevent this electrostatic charge build-up. We studied the electrostatic phenomenon in order to clarify the clinical aspects. The in vitro part of the study is related to the behaviour of the Medtronic Biopump and the Stockert Shiley roller pump--in combination with the use of a PVC or silicone pumpheader. Subsequently, we have investigated the influence of the rotation or flow of both types of blood pumps and occlusion settings on the roller pump. Furthermore, we tried to capture the electrical charge generated by the roller pumps in a capacitor and in some oxygenators with different types of heat exchanger. Finally, we tested the external CEL (Charge Equalization Line) and the internal 'Gold Wire' charge equalization systems, both patented by Medtronic. In the in vivo part of the study, 15 patients were divided into three groups of five patients each. In the first group a roller pump with a PVC pumpheader was evaluated and, in the second group, a roller pump with a silicone pumpheader. The third group consisted of the Medtronic Biopump. In all the groups, a Maxima Forté oxygenator with the external CEL protection was used. Owing to the fact that, at the time, the Maxima Forté 'Gold Wire' oxygenator was not available for clinical use, only the external CEL could be evaluated.

Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg

Cisplatin is the most important drug in the treatment of advanced ovarian cancer. The role of anthracyclines is controversial. We compared a combination of epirubicin plus cisplatin (EP) with a regimen of cyclophosphamide, epirubicin and cisplatin (CEP). Patients with stage Ic-IV ovarian cancer were randomized to receive either epirubicin 100 mg/m2 plus cisplatin 75 mg/m2 q 4 weeks or cyclophosphamide 500 mg/m2 plus epirubicin 75 mg/m2 plus cisplatin 50 mg/m2 q 4 weeks, which we considered the reference treatment based on our previous experience. Patients were initially debulked, followed by six cycles of chemotherapy, or in case primary debulking was insufficient or considered inappropriate, secondary debulking was attempted in selected cases after sufficient chemotherapy-induced regression. Optimal debulking was defined as residual lesions < or = 2 cm. A total of 210 patients (191 eligible) were randomized. Results did not show significant differences in all major endpoints (pathologically documented complete response and survival). The median survival for all patients was 34 months, for patients with stage III 26 months, for patients with stage IV 20 months and it has not been reached for patients with stage Ic-II. As no significant differences between an equitoxic regimen of EP and CEP were detected, it might be more useful to look again at the anthracyclines as part of combination chemotherapy instead of the alkylating agents.